Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Intratracheal instillation of anti-CD103 does not affect allergic airway inflammation in a mouse asthma model Source: Eur Respir J 2005; 26: Suppl. 49, 25s Year: 2005
Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
Anti-IL-5 antibody reduces the increase of CD34+ eosinophils in a mouse model of airway allergic eosinophilia Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Effect of anti-IgE therapy on microRNAs in the lungs of mice with allergen-driven airway remodeling Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
Effect of budesonide/formoterol combination on an airway hyperresponsiveness and inflammation model in mice Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Effects of budesonide/formoterol maintenance therapy on airway hyperresponsiveness and inflammation in an allergic rat model Source: Eur Respir J 2004; 24: Suppl. 48, 351s Year: 2004
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers Source: Eur Respir J 2013; 41: 239-241 Year: 2013
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice Source: Annual Congress 2008 - Novel mechanisms in the pathogenesis of pulmonary inflammation Year: 2008